BioCentury | Jun 29, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: June 2017

...or PI4KA could help treat AD. Chinese Academy of Sciences Distillery Therapeutics Phosphatidylinositol 4-kinase α (PI4KA...
BioCentury | Jun 27, 2017
Distillery Therapeutics

Neurology

...INDICATION: Alzheimer's disease (AD) Fruit fly studies suggest inhibiting EFR3A or PI4KA could help treat AD...
...of AD, knockout of the fruit fly homolog of EFR3A, knockout of PI4KA or a PI4KA...
...PI4KA inhibition in mouse models of AD. TARGET/MARKER/PATHWAY: EFR3 homolog A (EFR3A); phosphatidylinositol 4-kinase α (PI4KA...
BioCentury | Aug 28, 2014
Cover Story

Overcoming ibrutinib resistance

Imbruvica ibrutinib's unprecedented response rate in mantle cell lymphoma is generating excitement around the new drug, but as with many targeted cancer therapies, tumors can ultimately become resistant. A recent study from Weill Cornell Medical...
BioCentury | Jun 26, 2014
Targets & Mechanisms

PI3K inhibition: solid immunotherapy

Until now, inhibition of phosphoinositide 3-kinase-d in cancer has been limited to leukemias and lymphomas because the isoform is only expressed on immune cells. A new finding that links the kinase to T cell responses...
BioCentury | May 16, 2013
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Insulin receptor substrate 1 (IRS1); phosphatidylinositol 3-kinase catalytic subunit a-polypeptide (PIK3CA; p110a); phosphoinositide 3-kinase-a (PI3Ka) Cell culture and mouse studies...
BioCentury | May 24, 2012
Targets & Mechanisms

Getting selective for gamma

Cellzome AG and Exelixis Inc. have independently designed the first highly selective inhibitors of the g-isoform of phosphoinositide 3-kinase . 1,2 Exelixis plans to out-license its inhibitors, whereas last week's acquisition of Cellzome by GlaxoSmithKline plc...
BioCentury | May 17, 2012
Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Arrhythmia Phosphoinositide 3-kinase (PI3K) In vitro and mouse studies suggest some doses of PI3K inhibitors may induce long QT syndrome...
BioCentury | Mar 29, 2012
Distillery Therapeutics

Indication: Endocrine/metabolic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Obesity Phosphoinositide 3-kinase (PI3K); PI3Ka; PI3Kd; PTEN (MMAC1; TEP1) Mouse studies suggest inhibiting PI3K could help treat obesity. In transgenic...
BioCentury | Oct 13, 2011
Targets & Mechanisms

Getting fat off PI3Kgamma

A team of Swiss researchers has shown that knocking out an isoform of the cancer target phosphoinositide 3-kinase led to weight loss and increased insulin sensitivity in mice. 1 The challenge will be designing compounds...
BioCentury | May 12, 2011
Cover Story

Making the most of the host

...catalytic a (PI4KA) as an HCV-replication host cofactor. 5 His group is screening and developing PI4KA...
Items per page:
1 - 10 of 12